Supplementary Materials to Ansell et al. "Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban" (Thromb Haemost 2017; 117.2)

Suppl. Table 1: Mean PoC-PT and TEG-R pre- and post- ciraparantag in Period 2 of each cohort. To minimize inter-subject variability, the difference from their time-zero PoC-PT and TEG-R baseline readings (pre-ciraparantag in Period 1 and pre-edoxaban in Period 2) were normalized by the baseline on a per-subject basis to calculate percent reversal. The elevated coagulation parameters eventually return toward baseline following the pharmacokinetics of edoxaban and show little response to ciraparantag administration.

	Prothrombin Time mean (± SE)			TEG-R mean (± SE)			
Time Point, hours	Placebo	300 mg		Placebo	300 mg		
0 (pre-edoxaban)	20.4 (0.4)	21.1 (0.3)		9.2 (0.4)	8.8 (0.6)		
2.75 (Pre-ciraparantag)	46.5 (3.0)	39.6 (1.6)		14.2 (1.1)	12.4 /(0.7)		
10 min post ciraparantag	44.8 (4.6)	39.1 (1.3)		14.4 (1.1)	12.2 (0.7)		
3.5 hours post ciraparantag	43.9 (3.2)	38.9 (1.4)		12.9 (1.7)	12.5 (0.4)		
4 hours post ciraparantag	42.5 (3.6)	36.8 (1.6)		13.5 (0.8)	12.5 (0.6)		
15 hours post ciraparantag	25.9 (0.5)	24.5 (0.8)		10.4 (0.6)	11.4 (0.8)		
27 hours post ciraparantag	22.1 (0.5)	22.3 (0.6)		9.9 (0.4)	9.6 (0.4)		


SE- standard error of the mean. Data shown only for placebo and highest dose of ciraparantag. Results with lower doses were similar.

Suppl. Table 2: Statistical assessment of data points in Figure 3.

Mg PER977/hrs post PER977	10 min	30 min	45 min	1.0hr	1.5hr	2.0hr	4.0hr
25							
50	*			**			**
100		**	***	***	**		*
200	***	**	***	***	*	**	*
300	***	**	***	***	***	*	**

^{*}p<0.05; **p<0.01; ***p<0.001

Suppl. Figure 1: WBCT (whole-blood clotting time) correlates with the prothrombin time (PT) in whole blood from placebo and edoxaban treated patients.



Suppl. Figure 2: Change from baseline WBCT and PT correlated with edoxaban PK values

